MannKind (MNKD) Looks Good: Stock Adds 7.8% in Session – Tale of the Tape

February 10, 2015 Technicals 0

Zacks

MannKind Corp. (MNKD) was a big mover last session with its shares rising nearly 8% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained roughly 41% since Jan 21.

This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

MannKind currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%.

A better-ranked bio-med/gene stock is Affymetrix Inc. (AFFX) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply